导师类型

硕士生导师

办公地点

6教308

职称/职务

特聘副教授

电子邮箱

xinghong.zhao@sicau.edu.cn

研究方向

新型肽类抗菌剂（基因组发掘与生物合成）、仿生纳米载药系统、细菌耐药性防控

学术、技术组织任职/头衔

四川省特聘专家、荷兰皇家微生物学学会会员（2018年至今）、美国微生物学会会员（2023年至今）、Frontiers in Microbiology(IF=6.604, Top)客座编辑（Guest Editor）。

教育背景及工作经历

2021/08至今yl34511线路中心特聘副教授

2020/06–2021/08荷兰格罗宁根大学微生物与生化药学博士后

2017/08–2020/06荷兰格罗宁根大学微生物与生化药学博士

教学课程

生物技术制药、仪器分析（药）、药学专业英语

人才培养情况

在荷兰留学期间指导毕业硕士研究生1名，现正指导在读硕士生4名、本科生14名。

科研项目

（近五年）

1、天府英才工程专项，2023.04-2026.03，在研，主持

2、yl34511线路中心引进人才科研启动项目，202108-202607，在研，主持

3、四川省国际科技创新合作项目，202201-202312，在研，主持

主要论著、

代表性论文

现已发表SCI收录论文30余篇，累计被引800余次。近3年以第一作者在Cell Chemical biology、Antimicrobialagents and chemotherapy和ACS Synthetic Biology等业界公认的权威期刊发表新型肽类抗菌剂研究论文10篇。

[1]Xinghong Zhao, Zhibo Li, and Oscar P. Kuipers. "Mimicry of a Non-ribosomally Produced Antimicrobial, Brevicidine, by Ribosomal Synthesis and Post-translational Modification."Cell Chemical Biology,2020, 27(10): 1262-1271.（IF = 9.039，中科院升级版大类一区Top）

[2]Xinghong Zhao, Xinyi Zhong, Shinong Yang, Kai Deng, Lu Liu, Xu Song, Yuanfeng Zou, Lixia Li, Xun Zhou, Renyong Jia, Juchun Lin, Huaqiao Tang, Gang Ye, Jianqing Yang, Shan Zhao, Yifei Lang, Hongping Wan, Zhongqiong Yin, and Oscar P. Kuipers. "Elucidating the Mechanism of Action of the Gram-Negative-Pathogen-Selective Cyclic Antimicrobial Lipopeptide Brevicidine."Antimicrobial Agents and Chemotherapy,2023:e00010-23.（IF = 5.938，中科院升级版小类一区Top）

[3]Xinghong Zhao, Zhongqiong Yin, Eefjan Breukink, Gert N. Moll, and Oscar P. Kuipers. "An engineered double lipid II binding motifs-containing lantibiotic displays potent and selective antimicrobial activity against Enterococcus faecium."Antimicrobial Agents and Chemotherapy,2020, 64(6): e02050-19.（IF = 5.938，中科院升级版小类一区Top）

[4]Xinghong Zhao, Rubén Cebrián, Yuxin Fu, Rick Rink, Tjibbe Bosma, Gert N. Moll, and Oscar P. Kuipers. "High-throughput screening for substrate specificity-adapted mutants of the nisin dehydratase NisB."ACS Synthetic Biology,2020, 9(6): 1468-1478.（IF = 5.249，中科院升级版小类一区Top）

[5]Xinghong Zhao, and Oscar P. Kuipers. "Nisin-and ripcin-derived hybrid lanthipeptides display selective antimicrobial activity against Staphylococcus aureus."ACS Synthetic Biology2021, 10(7): 1703-1714.（IF = 5.249，中科院升级版小类一区Top）

[6]Xinghong Zhao, Yanli Xu, Jakob H. Viel, and Oscar P. Kuipers. "Semisynthetic Macrocyclic Lipo-lanthipeptides Display Antimicrobial Activity Against Bacterial Pathogens."ACS Synthetic Biology,2021, 10(8): 1980-1991.（IF = 5.249，中科院升级版小类一区Top）

[7]Xinghong Zhao, and Oscar P. Kuipers. "Synthesis of silver-nisin nanoparticles with low cytotoxicity as antimicrobials against biofilm-forming pathogens"Colloids and Surfaces B: Biointerfaces,2021, 206: 111965.（IF = 5.999，中科院升级版大类二区Top）

[8]Xinghong Zhao, and Oscar P. Kuipers. "BrevicidineB, a new member of the brevicidine family, displays an extended target specificity."Frontiers in Microbiology,2021, 12: 693117.（IF = 6.064，中科院升级版大类二区Top）

[9]Xinghong Zhao, Xiaoqi Wang, Rhythm Shukla, Raj Kumar, Markus Weingarth, Eefjan Breukink, and Oscar P Kuipers. "Brevibacillin 2V, a Novel Antimicrobial Lipopeptide With an Exceptionally Low Hemolytic Activity."Frontiers in Microbiology,2021, 12: 693725.（IF = 6.064，中科院升级版大类二区Top）

[10]Xinghong Zhao, Xiaoqi Wang, Rhythm Shukla, Raj Kumar, Markus Weingarth, Eefjan Breukink, and Oscar P Kuipers. "Brevibacillin 2V exerts its bactericidal activity via binding to Lipid II and permeabilizing cellular membranes."Frontiers in Microbiology,2021, 12: 694847.（IF = 6.064，中科院升级版大类二区Top）